Filing Flows › Guardant Health (GH) › How it makes money
How Guardant Health (GH) makes money
Guardant Health (GH) made $361M of revenue in the third quarter 2026 (Q3 2026), +36% from a year earlier. Oncology brought in $231M (64%); Screening brought in $67.6M (19%); Biopharma and data brought in $59.0M (16%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Oncology | $231M | 64.1% | +6% | +25% |
| Screening | $67.6M | 18.7% | +28% | +180% |
| Biopharma and data | $59.0M | 16.3% | -3% | +8% |
| Licensing and other | $3.1M | 0.9% | +52% | +60% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $361M | 100.0% |
| Income tax | $343K | 0.1% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $361M | +36% |
| Q2 2026 | $335M | +44% |
| Q1 2026 | $302M | +48% |
| Q4 2025 | $281M | +39% |
| Q3 2025 | $265M | +38% |
| Q2 2025 | $232M | +31% |
| Q1 2025 | $203M | +21% |
From Guardant Health's 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Guardant Health make money?
Guardant Health (GH) made $361M of revenue in the third quarter 2026 (Q3 2026), +36% from a year earlier. Oncology brought in $231M (64%); Screening brought in $67.6M (19%); Biopharma and data brought in $59.0M (16%).
What is Guardant Health's biggest business?
Oncology: $231M in the third quarter 2026, 64% of revenue, +25% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.